Prevalence Survey of Antimalarial Drug Resistance Markers
NCT03217851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000
Last updated 2022-06-28
Summary
Study is cross-sectional and observational with one-time dried-blood spot sample collection from persons with laboratory-confirmed uncomplicated Plasmodium falciparum malaria (mixed or monoinfection). Samples will be analysed for the presence of molecular markers of resistance to ACT partner drugs (gene amplifications and/or other mutations in pfmdr1, gene amplifications of pfpm2, and additional mutations which may be identified during the course of the trial) in the first instance. Testing to detect additional markers of antimalarial drug resistance will also be performed where feasible. Prevalence of mutations will be summarized and mapped to provide intelligence on antimalarial drug resistance in the region of interest.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Blood Collection
blood smear and/or rapid diagnostic
- DIAGNOSTIC_TEST
-
Dried Blood Spot
Dried Blood Spot on filter paper
Sponsors & Collaborators
-
Mahidol University
collaborator OTHER -
Worldwide Antimalarial Resistance Network
collaborator NETWORK -
Mahidol Oxford Tropical Medicine Research Unit
collaborator OTHER -
Myanmar Oxford Clinical Research Unit
collaborator OTHER -
Shoklo Malaria Research Unit
collaborator OTHER -
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
collaborator OTHER -
Oxford University Clinical Research Unit, Vietnam
collaborator OTHER -
Cambodia Oxford Medical Research Unit
collaborator UNKNOWN -
University of Oxford
lead OTHER
Principal Investigators
-
Francois Nosten, Prof · Shoklo Malaria Research Unit
-
Frank Smithuis, Prof · Myanmar Oxford Clinical Research Unit
-
Mayfong Mayxay, Prof · Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
-
Nguyen Thanh Thuy Nhien, Dr · Oxford University Clinical Research Unit, Vietnam
-
Arjen M. Dondorp, PhD · Mahidol Oxford Clinical Research Unit
Eligibility
- Min Age
- 6 Months
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-18
- Primary Completion
- 2021-12-24
- Completion
- 2021-12-24
Countries
- Thailand
Study Locations
More Related Trials
-
Drug Resistance Among Asymptomatic Infection
NCT03648411 ·Status: COMPLETED
-
Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers
NCT02427360 ·Status: COMPLETED
-
Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic
NCT02708199 ·Status: COMPLETED
-
Mass Screening and Treatment for Reduction of Falciparum Malaria
NCT04093765 ·Status: COMPLETED ·Phase: NA
-
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
NCT03783299 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Clinical Performance and Usability of Novel Malaria RDTs in Brazil
NCT05317117 ·Status: UNKNOWN ·Phase: NA
-
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
NCT03923725 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
NCT03355664 ·Status: COMPLETED ·Phase: PHASE3
-
Targeted Chemo-elimination (TCE) of Malaria
NCT01872702 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
NCT01659281 ·Status: COMPLETED ·Phase: NA
-
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
NCT02974348 ·Status: COMPLETED ·Phase: PHASE3
-
Artemisinin Resistance In Malaria Treated With IV Artesunate
NCT02640495 ·Status: WITHDRAWN
-
Combination Antimalarials in Uncomplicated Malaria
NCT00203801 ·Status: COMPLETED ·Phase: NA
-
Antimalarial Drug Resistance in Mali
NCT00127998 ·Status: COMPLETED ·Phase: NA
-
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
NCT05764746 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines
NCT05951595 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of a Digital Microscope for Malaria
NCT03512678 ·Status: COMPLETED
-
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
NCT02612545 ·Status: COMPLETED ·Phase: PHASE1
-
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar
NCT05025761 ·Status: UNKNOWN ·Phase: NA
-
Plasmodium Falciparum Artemisinin Resistance Vietnam
NCT01775592 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
NCT02223871 ·Status: COMPLETED ·Phase: PHASE1
-
A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
NCT02453308 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Phase2a Primaquine Dose Escalation Study
NCT01743820 ·Status: COMPLETED ·Phase: PHASE2
-
Artemisinin-resistant Malaria in Cambodia
NCT01736319 ·Status: COMPLETED
-
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
NCT02020330 ·Status: COMPLETED ·Phase: PHASE3